Animal (2015), 9:11, pp 1756–1759 © The Animal Consortium 2015. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. doi:10.1017/S1751731114002687



Effect of a single dose of *Saccharomyces cerevisiae* var. *boulardii* on the occurrence of porcine neonatal diarrhoea

L. R. Hancox¹, M. Le Bon², P. J. Richards^{1,2}, D. Guillou³, C. E. R. Dodd¹ and K. H. Mellits^{1,2†}

¹School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, Leicestershire, LE12 5RD, UK; ²Lallemand Animal Nutrition: Monogastric Centre of Excellence, University of Nottingham, Sutton Bonington Campus, Loughborough, Leicestershire, LE12 5RD, UK; ³Lallemand Animal Nutrition, 31702 Blagnac, France

(Received 14 March 2014; Accepted 2 September 2014; First published online 10 July 2015)

Piglet neonatal diarrhoea is an important issue in modern pig production and is linked to increased mortality and poor growth rates, affecting long-term pig health, increasing use of medication and cost of production. Saccharomyces cerevisiae var. boulardii (*SB*) is a probiotic yeast with documented clinical efficacy in the prevention and treatment of diarrhoeal diseases in humans. The objectives of the current study were to evaluate the effect of *SB* on occurrence and severity of neonatal diarrhoea in piglets, mortality and growth rate. Forty-six litters (606 piglets) were randomly allocated to a control or *SB* treatment (n = 23 per treatment). Within 24 h of farrowing, piglets assigned to the *SB* treatment received a single oral dose of a paste containing 3.3×10^9 CFU of *SB* CNCM I-1079. Piglets from the control litters received a placebo paste. Piglet weight, mortality and diarrhoea were recorded up to day 7 of age. It was shown that numbers of diarrhoea days were significantly correlated with increased mortality rate and reduced weight gain (P < 0.05). *SB* treatment had no effect on growth or mortality in diarrhoeic litters. However, *SB*-supplemented litters had significantly lower faecal scores, indicating firmer faeces (P < 0.01) and fewer numbers of diarrhoeic days (P < 0.01) during the 1st week of life. Reduction in the number of diarrhoeic litters compared with the control group was observed following the probiotic administration (P < 0.05). These results highlight the detrimental effects of neonatal diarrhoea on pre-weaning performance and suggest that *SB*, by reducing diarrhoea duration and severity, has the potential of improving enteric health in the early stages of life in pigs.

Keywords: probiotic, diarrhoea, Saccharomyces cerevisiae var. boulardii, pig

Implications

Enteric health and growth of the pre-weaning pig influences its lifelong production potential, therefore correct management of gut health during this time is essential. Considering the intensifying concerns over emerging antimicrobial resistance and that reduction in antibiotic use is a requirement in most countries, it is imperative to determine the efficacy of alternative treatments and prophylaxis such as probiotics. The current study demonstrates that administering the probiotic yeast *Saccharomyces cerevisiae* var. *boulardii* (SB) to piglets on the day of farrowing reduces occurrence of diarrhoea in the 1st week of life; therefore, application of SB may be used to improve pre-weaning enteric health.

Introduction

Historically, antibiotics have been used in pig medicine to treat and control bacterial enteric disease. In addition, use European Union and, considering the intensifying concerns over emerging antimicrobial resistance, antibiotic use, both frequency and class, has become more tightly controlled in veterinary medicine (European Commission, 2011; Millet and Maertens, 2011). Therefore, investment in alternative methods of controlling enteric disease is essential. Saccharomyces cerevisiae var. boulardii is a non-pathogenic, non-colonising, yeast. Several studies have shown that, in humans, SB is an efficacious and safe probiotic, which has proven efficacy against some enteric diseases including, but not limited to, Clostridium difficile-associated disease and rotavirus diarrhoea (McFarland, 2006; Grandy et al., 2010; McFarland, 2010). Data on the effect of SB on neonatal porcine health are limited, possibly because of practical limitations of administration to individual neonates commercially; however, studies have demonstrated that SB supplementation improves growth in post-weaning pigs (Bontempo et al., 2006; Le Bon et al., 2010).

of antibiotic growth promoters is now prohibited in the

Porcine neonatal diarrhoea is a welfare issue and may have an economic impact with regards to reduced production

[†] E-mail: Ken.Mellits@nottingham.ac.uk

and increased mortality. Therefore, the main objective of this study was to determine if a single oral dose of SB administered to neonatal pigs within 24 h of farrowing would reduce diarrhoea in the 1st week of life.

Material and methods

Experimental design

A randomised controlled trial was undertaken (November-December 2012) on a farrow-to-wean farm in Sarthe, France, with a history of neonatal diarrhoea. Commercial parent sows due to farrow in the same week were paired according to parity, and a treatment, SB or control, was randomly allocated (via coin flip, by an independent person) to each of the pairs. The trial was conducted during 2 consecutive weeks in identical housing; each treatment involved 23 identical pens (the experimental unit) each containing a sow with her litter, yielding 299 and 307 piglets for control and SB treatment, respectively. To test the hypothesis that reduction of diarrhoea by treatment would lead to an improvement of health and growth, the number of experimental replicates required was determined using previously recorded performance data available from this farm (mean average daily gain (ADG) during the 1^{st} week of life = 0.160 kg, s.d. = 0.041) to demonstrate an improvement of 15%in ADG by treatment, with a statistical power of 80% and significance of P < 0.05 using the equation:

 $n = (2\sigma^2(Z_\beta + Z_{\alpha/2})^2)/\text{Difference}^2$

where *n* is the sample size, σ the standard deviation, Z_{β} the *Z* value of power and Z_{α} the *Z* value of significance (Steel and Torrie, 1996). All trial personnel, including investigators, were blinded to treatment allocation; blinding was verified by anonymous survey. Euthanasia, only where necessary for welfare reasons, was carried out by manual blunt trauma to the cranium; this was performed by trained personnel. All animals in the study were monitored daily by a veterinary surgeon; no adverse effect of control or SB administration was noted.

Animals were treated according to standard farm practices unless stated otherwise. Sows were moved to farrowing pens 5 days before their expected farrowing date; pens had a slatted floor (1.6 m \times 2.5 m), farrowing crate (0.8 m \times 2 m) and an area of solid plastic flooring (triangular: 1.2 $m \times 0.85 m \times 1.5 m$) with a heat lamp suspended above for piglet comfort. Room temperature and humidity was measured hourly (mean 23.5°C (range 21.5°C to 25°C) and mean 67% (range 56.5% to 74.5%), respectively). To equilibrate litter size, neonatal piglets were cross-fostered within treatment group. On day 0 (day of birth), piglets were identified with a numbered colour-coded ear tag, weighed and administered a 3.3 ml oral dose of paste. Treatment litters received an individual dose of paste containing 3.3×10^9 CFU of dried SB (Levucell[®]SB, *S. cerevisiae* CNCM-I 1079; Lallemand Animal Nutrition, Blagnac, France); control litters received the identical paste with no probiotic addition (paste constituents: soya oil, cristobalite, icing sugar,

polysorbate 80, flavour). While being handled for paste administration, piglets also received a 1 ml, intra-muscular (IM) injection of amoxicillin (150 mg/ml, Vetrimoxin, CEVA animal health, Libourne, France); within 48 h of birth piglet teeth were filed, their tails docked via a heated cauterizer and they received an IM injection of iron (1 ml, 200 mg/ml Ferro2000; Coophavet, Saint-Herblon, France). At 4 days of age, piglets were given a 0.7 ml oral dose of the antiparasitic product, toltrazuril (50 mg/ml; Baycox, Bayer, Kiel, Germany) and male piglets were surgically castrated, all in accordance with routine farm practice. The trial was approved by the farm's veterinary consultant, and all procedures were compliant with French regulations and were approved by the University of Nottingham ethics committee.

Data collection. Between 0 and 7 days of piglet age, each pen floor was examined visually once daily for faecal consistency, by a single investigator blinded for treatment, and a score allocated to the entire pen using a faecal classification score system. If a score of 5 or more was allocated, the litter was determined to be diarrhoeic (Lewis and Heaton, 1997; Pedersen and Toft, 2011). Score 1 is classified as 'Separate hard lumps, like nuts', score 2 'Sausage-shaped, but lumpy', score 3 'Like a sausage but with cracks on the surface', score 4 'Like a sausage or snake, smooth and soft', score 5 'Soft blobs with clear cut edges', score 6 'Fluffy pieces with ragged edges, a mushy stool' and score 7 'Watery, no solid pieces, entirely liquid'. To monitor production, piglets were weighed individually at day 0 and day 7; mortality, natural and euthanasia, was recorded in the same period.

Statistical methods. For all statistical analysis, the litter (pen) served as the experimental unit (n = 23). For variables that recorded individual pig measurement (such as weight) the individuals were clustered for each litter and considered as random effect. Baseline characteristics of the two treatment groups were compared before administration of treatment using general ANOVA; mean and standard error of difference (s.e.d.) are reported for relevant variables (Table 1). Continuous data were found to be normally distributed and analysed using linear mixed models function in GenStat (14th Edition, GenStat, VSN International). For performance data (weight, ADG, mortality) and diarrhoea days, the statistical models included treatment as a fixed effect and litter size at day 0 as the random factor. The relationship between diarrhoea days and performances was evaluated using simple linear regression models. For categorical data: faecal scores and diarrhoeic status, the effect of treatment was analysed using χ^2 (with Yates' correction for 2 × 2 tables) and χ^2 for trend (GraphPad Software Inc., USA) using primary data.

Results

Effect of SB supplementation on neonatal diarrhoea and production

After treatment, SB-supplemented litters had significantly fewer days of diarrhoea over the 1st week of life compared to

Hancox, Le Bon, Richards, Guillou, Dodd and Mellits

Table 1 Effect of SB treatment on production and diarrhoea in neonatal pigs¹

Item	Control	SB	s.e.d.	<i>P</i> -value
Baseline				
Number of litters	23	23	-	-
Mean parity	3.65	3.83	0.63	-
Mean litter size	13.00	13.35	0.92	-
Mean initial birth weight (kg)	1.42	1.39	0.05	-
Production				
Mean mortality/litter	1.32	0.98	0.63	0.587
Mean ADG over 7 days (kg)	0.158	0.163	0.01	0.744
Diarrhoeal disease				
Mean number of diarrhoea days	3.92	2.43	0.53	0.008
Number of diarrhoeic litters	22	17	-	0.101

SB = Saccharomyces cerevisiae var. boulardii; s.e.d. = standard error of difference; ADG = average daily gain.

 ^1A single individual dose of control paste or SB CNCM-I 1079 (3.3 $\times 10^9$ CFU) was administered within 24 h of birth to individual piglets. Weight, mortality and diarrhoea are presented from day 1 to 7. n = 23 litters per treatment.

 Table 2 Effect of SB treatment on faecal scores of neonatal pigs¹

Score	core Control	
Score 3	10.08% (13)	12.31% (16)
Score 4	24.81% (32)	40.00% (52)
Score 5	41.86% (54)	35.38% (46)
Score 6	19.38% (25)	12.31% (16)
Score 7	3.88% (5)	0

SB = Saccharomyces cerevisiae var. boulardii.

¹A single individual dose of control paste or SB CNCM-I 1079 (3.3×10^9 CFU) was administered within 24 h of birth to individual piglets (n = 23 litters per treatment). Pen faecal scores were recorded daily from day 1 to 7. Score 1 is classified as 'Separate hard lumps, like nuts', score 2 'Sausage-shaped, but lumpy', score 3 'Like a sausage but with cracks on the surface', score 4 'Like a sausage or snake, smooth and soft', score 5 'Soft blobs with clear cut edges', score 6 'Fluffy pieces with ragged edges, a mushy stool' and score 7 'Watery, no solid pieces, entirely liquid'. Scores 1 and 2 were not detected during the study. Table shows the percentage of litters (and raw count) of each score for control and SB treatment between day 1 and 7. *P < 0.01 (χ^2 for trend on raw counts).

controls (P < 0.01; Table 1). This could not be attributed to sow parity, litter size or average birth weights as these were not significantly different between treatment groups (Table 1), although increasing sow parity correlated with number of diarrhoeic days (data not shown). SB litters also had significantly lower faecal scores, indicating firmer faeces, during the 1st week of life (Table 2, P < 0.01). Six SB litters experienced no diarrhoeic events compared with a single litter in the control group (Table 1). Analysing days independently, there was a similar number of diarrhoeic litters per group before treatment (day 0); after treatment. diarrhoeic litters decreased in the SB group and increased in the controls (day 3, and over days 1 to 7; P < 0.05, Figure 1). There was no statistically significant effect of SB on growth or mortality (Table 1). However, as expected, the number of diarrhoeic days was negatively correlated with ADG and average weight (both P < 0.01; Figure 2a and b). Moreover, there was a positive correlation between number of




Figure 1 Effect of Saccharomyces cerevisiae var. boulardii (SB) on number of diarrhoeic litters in the 1st week of life. *P < 0.05. A single individual dose of SB CNCM-I 1079 (3.3×10^9 CFU), or control paste was administered within 24 h of birth to individual piglets. n = 23 litters per treatment.




Figure 2 Effect of number of days of diarrhoea on average daily weight gain of piglets from day 0 to 7 (a); average weight at day 7 (b); and mortality from day 0 to 7 (c), independent of treatment, n = 46. Significant correlations: P < 0.01, P < 0.01 and P < 0.05, respectively. Error bars indicate standard error of the mean. Coefficients of determination (R^2) are indicated.

diarrhoeic days and mortality from day 0 to day 7 (P < 0.05; Figure 2c).

Discussion

The current study demonstrates that supplementation with a single dose of SB, within 24 h of birth, reduces both occurrence and severity of diarrhoea in piglets over the 1st week of life. Previous studies, in rats and humans, as well as our own unpublished data in pigs, have determined SB to be transient and non-colonising in the gastrointestinal tract (Blehaut *et al.*, 1989); this is consistent with our findings that a significant effect of SB was not demonstrated after day 3.

SB has known positive effects on reduction of enteric pathogens of pigs including Escherichia coli (Lessard et al., 2008; Collier et al., 2011), and in human studies C. difficileassociated disease, and rotavirus infection (McFarland, 2006; Grandy et al., 2010); however, we found no evidence of such effects (data not shown). Not all diarrhoea is caused by infectious agents; thus, the significant reduction in diarrhoea in this study, related to SB administration, could be due to the physiological effects of SB improving osmotic balance. In rat models, SB administration increases expression of sodium/glucose co-transporter-1, improving glucose, water and electrolyte re-absorption in the gut, encouraging fluid and electrolyte balance (Buts et al., 1999). Studies have also shown that SB causes an increase in activity of brush border enzymes, improving nutrient breakdown and absorption (Buts et al., 1994; Buts and De Keyser, 2006).

Commercial pig production aims to produce highly prolific sows, as this provides an opportunity to be more profitable, however, problems of large litters include chilling, inadequate colostrum transfer, increased heterogeneity, low birth weight/non-viability and crushing, as well as high incidence of neonatal diarrhoea. The issue of increasing litter size has been previously reviewed, and, as it is unlikely producers will cease attempting to increase litter size, good management might negate some issues it brings (Baxter *et al.*, 2013; Rutherford *et al.*, 2013). Thus, SB could have a role in this management, as the results of the current study shows it decreases neonatal diarrhoea.

The current study has shown the potential of SB supplementation by demonstrating the benefit of a single oral dose on enteric health of the pig. The results show that a single dose of SB on the day of farrowing significantly reduced number of diarrhoeic days experienced, and promoted lower faecal scores (firmer faeces) in the 1st week of life. It has been suggested that enteric health of the young pig can impact lifelong gut health (Mahan and Lepine, 1991; McOrist and Mellits, 2010). Therefore, because of the effect of SB on diarrhoea, and also the correlation between diarrhoea, mortality and growth, it may be suggested that continuous SB administration during the pre-weaning period could have significant effects on production.

Acknowledgements

This work was supported by grants from the BBSRC and Lallemand. M.L.B. and D.G. are employees of Lallemand Animal Nutrition. The authors acknowledge the technical assistance of Helen Davies, Elizabeth King and Rebecca Chandler-Bostock, and the staff of the trial farm. They thank Professor Ian Connerton, Dr Sabine Tötemeyer and Professor Julian Wiseman, for their careful and critical reading of this manuscript.

References

Baxter EM, Rutherford KMD, D'Eath RB, Arnott G, Turner SP, Sandoe P, Moustsen VA, Thorup F, Edwards SA and Lawrence AB 2013. The welfare implications of large litter size in the domestic pig II: management factors. Animal Welfare 22, 219–238.

Blehaut H, Massot J, Elmer GW and Levy RH 1989. Disposition kinetics of *Saccharomyces boulardii* in man and rat. Biopharmacuetics & Drug Disposition 10, 353–364.

Bontempo V, Di Giancamillo A, Savoini G, Dell'Orto V and Domeneghini C 2006. Live yeast dietary supplementation acts upon intestinal morpho-functional aspects and growth in weanling piglets. Animal Feed Science and Technology 129, 224–236.

Buts JP and De Keyser N 2006. Effects of *Saccharomyces boulardii* on intestinal mucosa. Digestive Diseases and Sciences 51, 1485–1492.

Buts JP, De Keyser N and De Raedemaeker L 1994. *Saccharomyces boulardii* enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatric Research 36, 522–527.

Buts JP, De Keyser N, Marandi S, Hermans D, Sokal EM, Chae YH, Lambotte L, Chanteux H and Tulkens PM 1999. *Saccharomyces boulardii* upgrades cellular adaptation after proximal enterectomy in rats. Gut 45, 89–96.

Collier CT, Carroll JA, Ballou MA, Starkey JD and Sparks JC 2011. Oral administration of *Saccharomyces cerevisiae boulardii* reduces mortality associated with immune and cortisol responses to *Escherichia coli* endotoxin in pigs. Journal of Animal Science 89, 52–58.

European Commission 2011. Communication from the Commission to the European Parliament and the Council: action plan against the rising threats from Antimicrobial Resistance. COM (2011) 748, Brussels. Retreived July, 7 2014, from http://ec.europa.eu/dgs/health_consumer/docs/communication_amr_2011_748_en.pdf

Grandy G, Medina M, Soria R, Teran C and Araya M 2010. Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. BMC Infectious Diseases 10, 253.

Le Bon M, Davies HE, Glynn C, Thompson C, Madden M, Wiseman J, Dodd CER, Hurdidge L, Payne G, Le Treut Y, Craigon J, Tötemeyer S and Mellits KH 2010. Influence of probiotics on gut health in the weaned pig. Livestock Science 133, 179–181.

Lessard M, Dupuis M, Gagnon N, Nadeau E, Matte JJ, Goulet J and Fairbrother JM 2009. Administration of *Pediococcus acidilatici* or *Saccharomyces cerevisiae boulardii* modulates development of porcine mucosal immunity and reduces intestinal bacterial translocation after *Escherichia coli* challenge. Journal of Animal Science 87, 922–934.

Lewis SJ and Heaton KW 1997. Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology 32, 920–924.

Mahan DC and Lepine AJ 1991. Effect of pig weaning weight and associated nursery feeding programs on subsequent performance to 105 kilograms body weight. Journal of Animal Science 69, 1370–1378.

McFarland LV 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of *Clostridium difficile* disease. American Journal of Gastroenterology 101, 812–822.

McFarland LV 2010. Systematic review and meta-analysis of *Saccharo-myces boulardii* in adult patients. World Journal of Gastroenterology 16, 2202–2222.

McOrist S and Mellits KH 2010. The important lifetime effects of intestinal gut health of pigs at weaning. The Veterinary Journal 184, 253–254.

Millet S and Maertens L 2011. The European ban on antibiotic growth promoters in animal feed: from challenges to opportunities. The Veterinary Journal 187, 143–144.

Pedersen KS and Toft N 2011. Intra- and inter-observer agreement when using a descriptive classification scale for clinical assessment of faecal consistency in growing pigs. Preventive Veterinary Medicine 98, 288–291.

Rutherford KMD, Baxter EM, D'Eath RB, Turner SP, Arnott G, Roehe R, Ask B, Sandoe P, Moustsen VA, Thorup F, Edwards SA, Berg P and Lawrence AB 2013. The welfare implications of large litter size in the domestic pig I: biological factors. Animal Welfare 22, 199–218.

Steel RGD and Torrie JH 1996. Principles and procedures of statistics: a biometrical approach. McGraw-Hill Inc., US.